- SION-109 is a small molecule targeting the interface between the ICL4 region and the NBD1 domain of the CFTR protein; designed to complement the company's NBD1 modulator portfolio - BOSTON, Jan. 24, ...
- Enrolling Phase 1 study of lead NBD1 modulator, SION-638, following IND clearance from the FDA; data expected in the second half of 2023 - - SION-109, targeting complementary mechanism ICL4, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results